Journal of Nanobiotechnology,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: Nov. 5, 2023
Abstract
Marine
resources
in
unique
marine
environments
provide
abundant,
cost-effective
natural
biomaterials
with
distinct
structures,
compositions,
and
biological
activities
compared
to
terrestrial
species.
These
marine-derived
raw
materials,
including
polysaccharides,
protein
components,
fatty
acids,
minerals,
etc.,
have
shown
great
potential
preparing,
stabilizing,
or
modifying
multifunctional
nano-/micro-systems
are
widely
applied
drug
delivery,
theragnostic,
tissue
engineering,
etc.
This
review
provides
a
comprehensive
summary
of
the
most
current
biomaterial-based
developed
over
past
three
years,
primarily
focusing
on
therapeutic
delivery
studies
highlighting
their
cure
variety
diseases.
Specifically,
we
first
provided
detailed
introduction
physicochemical
characteristics
biocomponents
state.
Furthermore,
assembly
processes,
functionalities
each
building
block,
thorough
evaluation
pharmacokinetics
pharmacodynamics
advanced
systems
effects
molecular
pathophysiological
processes
were
fully
elucidated.
Finally,
list
unresolved
issues
pivotal
challenges
applications,
such
as
standardized
distinction
long-term
biosafety
vivo,
feasibility
scale-up,
was
presented.
is
expected
serve
roadmap
for
fundamental
research
facilitate
rational
design
diverse
emerging
applications.
Graphical
Recent Patents on Anti-Cancer Drug Discovery,
Journal Year:
2022,
Volume and Issue:
18(2), P. 125 - 132
Published: July 14, 2022
Background:
Cancer
is
the
biggest
killer
that
threatens
human
health.
Poor
bioavailabil-ity
and
strong
drug
resistance
of
cancer
drugs
are
common
defects.
In
recent
years,
delivery
therapy
based
on
nanotechnology
has
become
a
focused
research
area,
nano
sys-tem
been
widely
studied
in
treatment.
Objective:
Based
articles
patents
published
application
systems
treatment
past
five
this
paper
summarizes
types
their
advantages
limitations
order
to
provide
reference
for
future
anticancer
systems.
Methods:
This
perspective
ad-vantages
proposes
development
direction
future.
Results:
review
patents,
we
found
system
mainly
divided
into
encapsulated
covalently
bound
nano-prodrug
system.
Its
reflected
enhancing
stability,
improving
bioavailability,
reducing
toxicity
better
diagnosis.
However,
new
field
science,
some
these
might
have
high
low
bioavailability;
off-target
phenomenon
often
occurs,
most
stud-ies
just
early
stage,
its
mechanism
action,
clinical
efficacy
patient
toler-ance,
remains
be
further
investigated.
Conclusion:
systematically
obtained
last
years.
Future
should
consider
potential
risks,
stable
efficient
designed
treat
can-cer
by
changing
or
functionalizing
nanomaterial.
Military Medical Research,
Journal Year:
2022,
Volume and Issue:
9(1)
Published: Dec. 12, 2022
Traditional
treatments
for
advanced
hepatocellular
carcinoma
(HCC),
such
as
surgical
resection,
transplantation,
radiofrequency
ablation,
and
chemotherapy
are
unsatisfactory,
therefore
the
exploration
of
powerful
therapeutic
strategies
is
urgently
needed.
Immunotherapy
has
emerged
a
promising
strategy
HCC
treatment
due
to
its
minimal
side
effects
long-lasting
memory
effects.
Recent
studies
have
demonstrated
that
icaritin
could
serve
an
immunomodulator
effective
immunotherapy
HCC.
Encouragingly,
in
2022,
soft
capsules
were
approved
by
National
Medical
Products
Administration
(NMPA)
China
However,
efficacy
clinical
practice
impaired
poor
bioavailability
unfavorable
vivo
delivery
efficiency.
Recently,
functionalized
drug
systems
including
stimuli-responsive
nanocarriers,
cell
membrane-coated
living
cell-nanocarrier
been
designed
overcome
shortcomings
drugs,
low
limited
efficiency
well
Taken
together,
development
icaritin-based
nanomedicines
expected
further
improve
Herein,
we
compared
different
preparation
methods
icaritin,
interpreted
immune
microenvironment
mechanisms
underlying
HCC,
discussed
both
design
with
high
loading
latest
progress
immunotherapy.
Finally,
prospects
promote
translation
proposed.
International Journal of Nanomedicine,
Journal Year:
2023,
Volume and Issue:
Volume 18, P. 4121 - 4142
Published: July 1, 2023
Introduction:
Currently,
conventional
treatments
of
hepatocellular
carcinoma
(HCC)
are
not
selective
enough
for
tumor
tissue
and
lead
to
multidrug
resistance
drug
toxicity.
Although
sorafenib
(SOR)
is
the
standard
first-line
systemic
therapy
approved
clinical
treatment
HCC,
its
poor
aqueous
solubility
rapid
clearance
result
in
low
absorption
efficiency
severely
limit
use
local
treatment.
Methods:
Herein,
we
present
synthesis
biodegradable
polymeric
Poly
(D,
L-Lactide-co-glycolide)
(PLGA)
particles
loaded
with
SOR
(PS)
by
emulsion-solvent
evaporation
process.
The
carefully
characterized
focusing
on
particle
size,
surface
charge,
morphology,
loading
content,
encapsulation
efficiency,
vitro
stability,
release
behaviour
tested
HepG2
cells.
Additionally,
PLGA
have
been
coupled
side
emitting
optical
fibers
(
se
OF)
integrated
a
microfluidic
device
light-triggered
release.
Results:
PS
size
248
nm,
tunable
charge
uniform
spherical
shape
without
aggregation.
shows
89.7%
highest
(8.9%)
between
SOR-loaded
formulations.
Treating
cells
containing
at
7.5
μM
their
viability
dampened
40%,
30%
17%
after
48,
129
168
hours
incubation,
respectively.
Conclusion:
high
sustained
profile
cellular
uptake
corroborate
enhanced
cytotoxicity
effect
HepG2.
With
prospect
developing
biomedical
tools
control
spatial
temporal
drugs,
successfully
demonstrated
potentiality
OF
carriers.
Our
prototypical
system
paves
way
new
devices
integrating
microfluidics,
fibers,
advanced
carriers
capable
deliver
minimally
invasive
locoregional
cancer
treatments.
Graphical
Abstract:
Keywords:
poly(lactic-co-glycolic
acid),
sorafenib,
emulsion
solvent
technique,
carcinoma,
fiber,
microfluidics
Molecular Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
20(10), P. 4922 - 4941
Published: Sept. 12, 2023
Cardiovascular
diseases
(CVDs)
refer
to
a
collection
of
conditions
characterized
by
abnormalities
in
the
cardiovascular
system.
They
are
global
problem
and
one
leading
causes
mortality
disability.
Nanotheranostics
implies
combination
diagnostic
therapeutic
capabilities
inside
single
nanoscale
platform
that
has
allowed
for
significant
advancement
diagnosis
therapy.
These
advancements
being
developed
improve
imaging
capabilities,
introduce
personalized
therapies,
boost
disease
patient
treatment
outcomes.
Significant
progress
been
achieved
integration
within
nanocarriers.
In
case
disease,
nanoparticles
provide
targeted
delivery
therapeutics,
genetic
material,
photothermal,
agents.
Directing
monitoring
movement
these
may
be
done
with
pinpoint
accuracy
using
modalities
such
as
magnetic
resonance
(CMR),
computed
tomography
(CT),
positron
emission
(PET),
photoacoustic/ultrasound,
fluorescence
imaging.
Recently,
there
an
increasing
demand
noninvasive
multimodal
nanotheranostic
platforms.
platforms,
various
technologies
optical
integrated
into
nanoparticle.
This
helps
acquiring
more
accurate
descriptions
provides
clues
diagnosis.
Advances
surface
functionalization
methods
have
strengthened
potential
application
nanotheranostics
this
Review,
we
covered
impact
nanomedicine
on
CVDs.
Additionally,
discussed
recently
CVDs
Moreover,
CMR,
CT,
PET,
ultrasound,
photoacoustic
discussed.
We
limited
our
discussion
nanomaterials
based
clinical
trials
their
patents.
Materials Today Bio,
Journal Year:
2023,
Volume and Issue:
20, P. 100673 - 100673
Published: June 1, 2023
Glioma
is
one
of
the
most
serious
central
nervous
system
diseases,
with
high
mortality
and
poor
prognosis.
Despite
continuous
development
existing
treatment
methods,
median
survival
time
glioma
patients
still
only
15
months.
The
main
difficulties
are
invasive
growth
obstruction
blood-brain
barrier
(BBB)
to
drugs.
With
rapid
advancements
in
nanotechnology,
inorganic
nanoparticles
(INPs)
have
shown
favourable
application
prospects
diagnosis
glioma.
Due
their
extraordinary
intrinsic
features,
INPs
can
be
easily
fabricated,
while
doping
other
elements
surface
modification
by
biological
ligands
used
enhance
BBB
penetration,
targeted
delivery
biocompatibility.
Guided
theranostics
improve
efficacy
traditional
methods
such
as
chemotherapy,
radiotherapy
gene
therapy.
New
strategies,
immunotherapy,
photothermal
photodynamic
therapy,
magnetic
hyperthermia
multifunctional
nanoplatforms,
also
been
facilitated
INPs.
This
review
emphasizes
current
state
research
clinical
applications
INPs,
including
targeting
penetration
enhancement
vivo
vitro
biocompatibility,
diagnostic
strategies.
As
such,
it
provides
insights
for
novel
RSC Advances,
Journal Year:
2024,
Volume and Issue:
14(28), P. 20152 - 20162
Published: Jan. 1, 2024
Synergistic
photodynamic
therapy
(PDT)
with
other
therapeutic
modalities
can
enhance
the
efficacy
of
tumor
treatment
and
reduce
adverse
effects
associated
drug
leakage
off-target
accumulation.
Drug Design Development and Therapy,
Journal Year:
2024,
Volume and Issue:
Volume 18, P. 2921 - 2949
Published: July 1, 2024
Abstract:
Inflammatory
bowel
disease
(IBD)
is
a
chronic,
non-specific
inflammatory
condition
characterized
by
recurring
inflammation
of
the
intestinal
mucosa.
However,
existing
IBD
treatments
are
ineffective
and
have
serious
side
effects.
The
etiology
multifactorial
encompasses
immune,
genetic,
environmental,
dietary,
microbial
factors.
nanoparticles
(NPs)
developed
based
on
specific
targeting
methodologies
exhibit
great
potential
as
nanotechnology
advances.
Nanoparticles
defined
particles
between
1
100
nm
in
size.
Depending
their
size
surface
functionality,
NPs
different
properties.
A
variety
nanoparticle
types
been
employed
drug
carriers
for
treatment
(IBD),
with
encouraging
outcomes
observed
experimental
models.
They
increase
bioavailability
drugs
enable
targeted
delivery,
promoting
localized
thus
enhancing
efficacy.
Nevertheless,
numerous
challenges
persist
translation
from
nanomedicine
to
clinical
application,
including
enhanced
formulations
preparation
techniques,
safety
profiles,
so
forth.
In
future,
it
will
be
necessary
scientists
clinicians
collaborate
order
study
mechanisms,
develop
new
delivery
strategies,
screen
nanomedicines.
Keywords:
nanoparticles,
diseases,
passive
targeting,
active
system
